The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Open accessAbstract
Deregulation of the cyclin D‐CDK4/6‐INK4‐RB pathway leading to uncontrolled cell proliferation, is frequently observed in breast cancer. Currently, three selective CDK4/6 inhibitors have been FDA approved: palbociclib, ribociclib and abemaciclib. Despite promising clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitors has limited the success of these treatments; therefore, the development of various strategies to overcome this resistance is of great importance. We highlight the various mechanisms that are directly or indirectly responsible for resistance to CDK4/6 inhibitors, categorizing them into two broad groups; cell cycle‐specific mechanisms and cell cycle‐nonspecific mechanisms. Elucidation of the diverse mechanisms through which resistance to CDK4/6 inhibitors occurs, may aid in the design of novel therapeutic strategies to improve patient outcomes. This review summarizes the currently available knowledge regarding mechanisms of resistance to CDK4/6 inhibitors, and possible therapeutic strategies that may overcome this resistance as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“The p16, a member of INK4 family and a natural inhibitor of CDK4, is an important tumor suppressor involved in the regulation of cell cycle.(31) Naturally, p16 works as a tumor suppressor in the presence of functional RB because CDK4/6 (a target of p16) requires RB for its own kinase activity.”
BackgroundTransitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Self-citationAP-1 in cell proliferation and survival
Shaulian, E., & Karin, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204383 · Cited by 1,736
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Self-citationCDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Incidence and Mortality and Epidemiology of Breast Cancer in the World
Ghoncheh, M., Pournamdar, Z., & Salehiniya, H. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.s3.43 · Cited by 1,115
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Self-citationMoustakas, A., & Heldin, C.-H. (2005) · Journal of Cell Science · doi:10.1242/jcs.02554 · Cited by 958
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Du, B., & Shim, J. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 807
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770 · cited 1×
“In addition, CDK6 phosphorylated nuclear factor of activated T cell 4 (NFAT4) and suppressed its activity, resulting in reduced IL2 levels, whereas CDK4/6 inhibitors increased IL2 levels by dephosphorylating NFAT4 and enhancing its activity.(105) Taken together, CDK4/6 inhibition potentiates anti-tumor immunity and en…”
BackgroundHerrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
Targeting CDK4/6 in patients with cancer
Hamilton, E., & Infante, J. R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.002 · Cited by 481
Cycling to Cancer with Cyclin D1
Diehl, J. A. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.72 · Cited by 475
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
Brooks, A. N., Kilgour, E., & Smith, P. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0699 · Cited by 446
Growth suppression by p16ink4 requires functional retinoblastoma protein
Medema, R. H., Herrera, R. E., Lam, F., & Weinberg, R. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6289 · Cited by 433
Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 415
Targeting WEE1 Kinase in Cancer
Matheson, C. J., Backos, D. S., & Reigan, P. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.006 · Cited by 408
Condorelli, R., Spring, L., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., Dubois, J., Nagy, R. J., Lanman, R. B., Iafrate, A. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx784 · Cited by 394
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Kuukasjärvi, T., Kononen, J., Helin, H., Holli, K., & Isola, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2584 · Cited by 358
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.012 · Cited by 313
Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1): Miniperspective
Ye, N., Ding, Y., Wild, C., Shen, Q., & Zhou, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5004733 · Cited by 307
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Konecny, G. E., Winterhoff, B., Kolarova, T., Qi, J., Manivong, K., Dering, J., Yang, G., Chalukya, M., Wang, H.-J., Anderson, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2307 · Cited by 302
Vijayaraghavan, S., Karakas, C., Doostan, I., Chen, X., Bui, T., Yi, M., Raghavendra, A. S., Zhao, Y., Bashour, S. I., Ibrahim, N. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15916 · Cited by 292
Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P., & Knudsen, E. S. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16776 · Cited by 286
Parise, C. A., & Caggiano, V. (2014) · Journal of Cancer Epidemiology · doi:10.1155/2014/469251 · Cited by 269
Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K.-M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sánchez, V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2653 · Cited by 244
Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21195 · Cited by 226
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001613107 · Cited by 223
Smith, L. M., Wise, S. C., Hendricks, D. T., Sabichi, A. L., Bos, T., Reddy, P., Brown, P. H., & Birrer, M. J. (1999) · Oncogene · doi:10.1038/sj.onc.1202989 · Cited by 213
Franco, J., Witkiewicz, A. K., & Knudsen, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2270 · Cited by 207
Tewari, D., Nabavi, S. F., Nabavi, S. M., Sureda, A., Farooqi, A. A., Atanasov, A. G., Vacca, R. A., Sethi, G., & Bishayee, A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.014 · Cited by 205
Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
Cip/Kip proteins: more than just CDKs inhibitors: Figure 1.
Denicourt, C., & Dowdy, S. F. (2004) · Genes & Development · doi:10.1101/gad.1205304 · Cited by 203
Cen, L., Carlson, B. L., Schroeder, M. A., Ostrem, J. L., Kitange, G. J., Mladek, A. C., Fink, S. R., Decker, P. A., Wu, W., Kim, J.-S., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos114 · Cited by 189
Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity
Larochelle, S., Pandur, J., Fisher, R. P., Salz, H. K., & Suter, B. (1998) · Genes & Development · doi:10.1101/gad.12.3.370 · Cited by 188
Michaloglou, C., Crafter, C., Siersbaek, R., Delpuech, O., Curwen, J. O., Carnevalli, L. S., Staniszewska, A. D., Polanska, U. M., Cheraghchi-Bashi, A., Lawson, M., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0537 · Cited by 177
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
Hart, C. D., Migliaccio, I., Malorni, L., Guarducci, C., Biganzoli, L., & Di Leo, A. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.99 · Cited by 169
A Cdk7-Cdk4 T-Loop Phosphorylation Cascade Promotes G1 Progression
Schachter, M. M., Merrick, K. A., Larochelle, S., Hirschi, A., Zhang, C., Shokat, K. M., Rubin, S. M., & Fisher, R. P. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.04.003 · Cited by 169
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
Corona, S. P., & Generali, D. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s137783 · Cited by 165
Malorni, L., Piazza, S., Ciani, Y., Guarducci, C., Bonechi, M., Biagioni, C., Hart, C. D., Verardo, R., Leo, A. D., & Migliaccio, I. (2016) · Oncotarget · doi:10.18632/oncotarget.12010 · Cited by 162
Chittaranjan, S., Bortnik, S. B., Dragowska, W. H., Xu, J., Abeysundara, N., Leung, A., Go, N. E., DeVorkin, L., Weppler, S. A., Gelmon, K. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2060 · Cited by 158
Zupkovitz, G., Grausenburger, R., Brunmeir, R., Senese, S., Tischler, J., Jurkin, J., Rembold, M., Meunier, D., Egger, G., Lagger, S., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01500-09 · Cited by 146
Redundant angiogenic signaling and tumor drug resistance
Gacche, R. N., & Assaraf, Y. G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.002 · Cited by 141
Efeyan, A., Ortega-Molina, A., Velasco-Miguel, S., Herranz, D., Vassilev, L. T., & Serrano, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0200 · Cited by 140
Phosphorylation of p21 in G2/M Promotes Cyclin B-Cdc2 Kinase Activity
Dash, B. C., & El‐Deiry, W. S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.3364-3387.2005 · Cited by 139
Liu, F., & Korc, M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0562 · Cited by 135
Clark, A. S., Karasic, T. B., DeMichele, A. M., Vaughn, D. J., O’Hara, M. H., Perini, R. F., Zhang, P. J., Lal, P., Feldman, M. D., Gallagher, M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4701 · Cited by 133
Cyclin D1, Id1 and EMT in breast cancer
Tobin, N. P., Sims, A. H., Lundgren, K., Lehn, S., & Landberg, G. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-417 · Cited by 125
Etemadmoghadam, D., Au‐Yeung, G., Wall, M., Mitchell, T. J., Kansara, M., Loehrer, E. A., Batzios, C., George, J., Ftouni, S., Weir, B. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1337 · Cited by 120
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
Taylor‐Harding, B., Aspuria, P.-J. P., Agadjanian, H., Cheon, D., Mizuno, T., Greenberg, D. N., Allen, J. R., Spurka, L., Funari, V. A., Spiteri, E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2673 · Cited by 117
Transcriptional Regulation of AKT Activation by E2F
Chaussepied, M., & Ginsberg, D. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.11.003 · Cited by 113
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Laroche-Clary, A., Chaire, V., Algeo, M.-P., Derieppe, M.-A., Loarer, F. L., & Italiano, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0482-3 · Cited by 111
CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
Olanich, M. E., Sun, W., Hewitt, S. M., Abdullaev, Z., Pack, S., & Barr, F. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2955 · Cited by 102
Hoffmann, J., Bohlmann, R., Heinrich, N., Hofmeister, H., Kroll, J., Künzer, H., Lichtner, R. B., Nishino, Y., Parczyk, K., Sauer, G., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh022 · Cited by 87
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
Guarducci, C., Bonechi, M., Boccalini, G., Benelli, M., Risi, E., Leo, A. D., Malorni, L., & Migliaccio, I. (2017) · Breast Care · doi:10.1159/000484167 · Cited by 84
Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells
The, I., Ruijtenberg, S., Bouchet, B. P., Cristobal, A., Prinsen, M. B. W., van Mourik, T., Koreth, J., Xu, H., Heck, A. J. R., Akhmanova, A. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms6906 · Cited by 82
Correale, P., Botta, C., Cusi, M. G., Vecchio, M. T. D., Santi, M. M. D., Savellini, G. G., Bestoso, E., Apollinari, S., Mannucci, S., Marra, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26181 · Cited by 77
Rb/E2F4 and Smad2/3 link survivin to TGF-β-induced apoptosis and tumor progression
Yang, J., Song, K. W., Krebs, T. L., Jackson, M. W., & Danielpour, D. (2008) · Oncogene · doi:10.1038/onc.2008.165 · Cited by 76
Cell cycle progression without cyclin E/CDK2
Gladden, A. B., & Diehl, J. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00217-4 · Cited by 67
Zelivianski, S., Cooley, A. E., Kall, R., & Jeruss, J. S. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0537 · Cited by 65
Finn, R., Jiang, Y., Rugo, H. S., Moulder, S., Im, S., Gelmon, K. A., Dieras, V. C., Martín, M., Joy, A. A., Toi, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw435.05 · Cited by 55
Laubli, H. P., Müller, P., D’Amico, L., Buchi, M., Kashyap, A. S., & Zippelius, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2136-x · Cited by 53
Demuth, C., Andersen, M. N., Jakobsen, K. R., Madsen, A. T., & Sørensen, B. S. (2017) · Oncotarget · doi:10.18632/oncotarget.19920 · Cited by 35
Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer
Kersh, A. E., Ng, S., Chang, Y. M., Sasaki, M., Thomas, S. N., Kissick, H. T., Lesinski, G. B., Kudchadkar, R. R., Waller, E. K., & Pollack, B. P. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1028 · Cited by 33
Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway
Kundu, N., Brekman, A., Kim, J. Y., Xiao, G., Gao, C., & Bargonetti, J. (2017) · Oncotarget · doi:10.18632/oncotarget.18147 · Cited by 26
Shen, Q., Uray, I. P., Li, Y., Zhang, Y., Hill, J. L., Xu, X.-C., Young, M. R., Gunther, E. J., Hilsenbeck, S. G., Colburn, N. H., et al. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0034 · Cited by 25
Slamon, D. J., Neven, P., Chia, S., Im, S., Fasching, P. A., Laurentiis, M. D., Petráková, K., Bianchi, G., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1000 · Cited by 23
Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
Sahores, A., May, M., Sequeira, G. R., et al. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009618666171214114706 · Cited by 22
p16INK4a expression in retinoblastoma: a marker of differentiation grade
Liu, Y., Zhong, X., Wan, S., Zhang, W., Lin, J., Zhang, P., & Li, Y. (2014) · Diagnostic Pathology · doi:10.1186/s13000-014-0180-1 · Cited by 20
Jin, S., Fang, W., Liu, X., Xing, S., Zhan, J., Ma, Y., Huang, Y., Zhou, N., Zhao, H., & Zhang, L. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s112158 · Cited by 19
Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer
Flaum, L., & Gradishar, W. J. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-70197-4_9 · Cited by 19
Reinforcing targeted therapeutics with phenotypic stability factors
Yaswen, P. (2014) · Cell Cycle · doi:10.4161/15384101.2014.985071 · Cited by 18
Ramanujan, A., & Tiwari, S. (2016) · Bioscience Reports · doi:10.1042/bsr20160152 · Cited by 18
Fibroblast Growth Factor Receptor (FGFR) as a Therapeutic Target in Lung and Head and Neck Cancer
Chae, Y. K., Pai, S. G., Sun, P., Costa, R. L. B., Matsangou, M., Agulnik, M., & Giles, F. J. (2016) · American Journal of Hematology / Oncology® · Cited by 9
Abstract P4-03-16: Cyclin E affects Smad3 pathway in trastuzumab resistant HER2+ breast cancer
Decker, J. T., Wan, L., Shea, L., & Jeruss, J. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-p4-03-16 · Cited by 2
Cited by
Exploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
Wang, T.-H., Chen, C.-C., Leu, Y.-L., Lee, Y.-S., Lian, J.-H., Hsieh, H.-L., & Chen, C.-Y. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.12.009 · Cited by 49
Metadata
- Authors
- Pandey, K., An, H., Kim, S. K., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2019-01-07
- Volume
- 145
- Issue
- 5
- Pages
- 1179-1188
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2902401096
- Cited by
- 361
- References
- 96
- FWCI
- 21.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.